Patients already receiving erythropoietin or granulocyte colony stimulating factor (GCSF) for treatment of HIV-related cytopenia are eligible
Erythropoietin or erythrocyte stimulating agents:  days
Received marrow stimulating factors:
Prior exposure to drugs that are antagonists of colony stimulating factor- receptor (CSFR) like but not limited to emactuzumab (RG) (Roche), PLX (Plexicon), and JNJ (J & J)
Patients may have had no prior systemic therapy except\r\n* Localized emergency radiation to sites of life threatening or functioning disease\r\n* No more than  cycle of chemotherapy according to low or intermediate risk regimens prior to determination of MYCN amplification and histology, as long as the patient DID NOT receive granulocyte colony-stimulating factor (G-CSF) as part of that therapy
Received transfusion of blood products or administration of colony stimulating factors within  weeks prior to the first dose of treatment.
Patients who are planned to receive the following medications concurrent with radiation: granulocyte stimulating factor (G-CSF), bevacizumab, cyclosporine, antitumor necrosis factor agents, amifostine
Active treatment with growth factors such as erythropoietin stimulating agent (ESA), granulocyte colony-stimulating factor (GCSF), or thrombopoietin stimulating factor within  weeks of registration
DONOR: known allergy to granulocyte colony-stimulating factor (G-CSF) or to Escherichia Coli (E. Coli)-derived recombinant protein products
Inability to purify >= . x ^ CD-enriched cells/kg of patient weight from the pooled granulocyte-colony stimulating factor (G-CSF) mobilized leukapheresis products
DONOR: Donor unfit to receive granulocyte colony-stimulating factor (G-CSF) and undergo apheresis.
Currently or previously being on erythrocyte stimulating agents (ESA) and granulocyte colony stimulating factors (G-CSF)
Have had previous treatment for HCL, including purine analogs, rituximab, and other investigational agents; previous treatment with transfusions and other supportive care such as granulocyte colony-stimulating factor (G-CSF) and erythropoietin are allowed
HLA-MATCHED UNRELATED DONOR: Only granulocyte colony-stimulating factor (G-CSF) mobilized PBSC will be permitted as a HSC source on this protocol
Patients must be able to meet the criteria without transfusion or receipt of colony stimulating factors within  weeks before obtaining sample
Patients must not require support to maintain adequate blood counts, as defined by:\r\n* Patients must not have received a transfusion (platelets or red blood cells) =<  weeks prior to initiating protocol therapy\r\n* Patient must not have received colony stimulating factors (eg, granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within  weeks prior initiating protocol therapy\r\n* Participant has had any known grade  or  anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted >  weeks and was related to the most recent treatment
If currently receiving erythroid stimulating agents (ESA) with plans to continue during study, less than  months duration of therapy with ESA prior to screening or dose escalation performed within  months of screening or addition of granulocyte colony stimulating factor (GCSF) to ESA within  months of screening
Contraindication to CE melphalan or any of the required supportive treatments, including hypersensitivity to granulocyte colony stimulating factor (G-CSF) or pegfilgrastim
Concomitant therapy with bisphosphonates, RANKL inhibitors or growth-colony-stimulating factors (G-CSF) is allowed as per physician decision
Use of hematopoietic colony-stimulating growth factors (eg, G-CSF, GMCSF, M-CSF) ?  weeks prior start or study drug. Patients must have completed therapy at least  weeks before the screening period begins with any hematopoietic colony-stimulating growth factors. An erythroid stimulating agent is allowed as long as it was initiated at least  weeks prior to the first dose of study treatment and the patient is not red blood cell transfusion dependent
Peripheral absolute neutrophil count (ANC) >= /uL in absence of granulocyte colony stimulating factor (GCSF) for  hours (hrs) or pegylated (peg)-GCSF for  days
No PEGylated granulocyte colony stimulating factor (PEG-GCSF) within  days of virus administration (day )
Both granulocyte-colony stimulating factor (G-CSF) stimulated peripheral blood grafts and bone marrow grafts will be the priority, although bone marrow graft source will be allowed based upon donor preference
Biopsy-proven unresectable, metastatic melanoma refractory to standard immunotherapy drugs or regimens, including prior treatment with aldesleukin (IL-), granulocyte-macrophage colony-stimulating factor (GM-CSF), ipilimumab, nivolumab, pembrolizumab, and/or Imlygic (talimogene laherparepvec [T-VEC]); prior clinical trial participation or treatment with molecularly targeted agents (i.e. vemurafenib/cobimetinib, dabrafenib/trametinib) or chemotherapy (i.e. temozolomide, dacarbazine, platinum, or taxanes) is permitted
Hemoglobin >=  g/dL\r\n* Note: blood transfusion will be allowed for patients with hemoglobin <  g/dl and granulocyte colony-stimulating factor (G-CSF) is allowed for neutropenic patients at time of enrollment
Concurrent use of any other agent for MDS, CMML, or AML; growth factor use with epoetin, darbepoetin, or granulocyte colony-stimulating factor must be terminated at least  weeks before initiation of study treatment
Participants already receiving erythropoietin or colony-stimulating factor therapy are eligible for participation, although the latter must be discontinued at least  hours prior to receiving chemotherapy
Unable or unwilling to discontinue use of prohibited medications within  days prior to randomization and while on treatment:\r\n* No chronic treatment with systemic steroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed\r\n* Growth factors (e.g. granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [G-GM-CSF], erythropoietin, platelets growth factors etc.) are not to be administered prophylactically but may be prescribed by the treating physician for rescue from severe hematologic events\r\n* Live vaccines must not be administered to patient \r\n* Drugs known to be strong inhibitors or inducers of the isoenzyme cytochrome P family  subfamily A member  (CYPA) must not be administered as systemic therapy; drugs or substances known to be moderate inhibitors or inducers of CYPA should be avoided if possible or used subject to caution; co-administration with strong or moderate inhibitors of P-glycoprotein (PgP) should be avoided if possible, or used subject to caution; concomitant use of Seville orange, star fruit, grapefruit and their juices should be avoided
Any previous cytotoxic, cytostatic, hormonal, biological or immunological treatment for MDS (Erythropoietin-stimulating agent (ESA) with or without granulocyte colony stimulating factor (G-CSF) are allowed under certain conditions, see exclusion criterion # ).
DONOR: Donors must consent and be eligible to undergo granulocyte colony-stimulating factor (GCSF) mobilization and PBSC harvest; marrow is not allowed as a source of stem cells on this study
Use of any other standard anti-neoplastic drug or growth factor (e.g., anagrelide, granulocyte colony-stimulating factor [G-CSF], Revlimid, clofarabine) except hydroxyurea or experimental drugs, with the exception of ruxolitinib, less than  days or -half lives prior to starting study therapy and/or lack of recovery from all toxicity from previous therapy to grade  or better
Use of hematopoietic colony-stimulating growth factors (eg, G-CSF, GMCSF, M-CSF) ?  weeks prior to start of study drug. Patients must have completed therapy at least  weeks before the screening period begins with any hematopoietic colony-stimulating growth factors. An erythroid stimulating agent is allowed as long as it was initiated at least  weeks prior to the first dose of study treatment and the patient is not red blood cell transfusion dependent
Colony stimulating factors within  weeks of study
Subjects who require the use of granulocyte colony stimulating factors (GCSF) for prophylaxis of neutropenia.
Participants must have received their last dose of short acting colony stimulating factor, such as filgrastim or sargramostim at least  hours prior to enrollment and their last dose of long-acting colony stimulating factors, such as PEG-filgrastim at least  days prior to enrollment
Receipt of colony stimulating factor filgrastim, pegfilgrastim, or sargramostim within  days prior to Day .
Hemoglobin count greater than or equal to  g/dL or greater than or equal to . mmol/L\r\n* Note: ANC, platelets, hemoglobin requirement cannot be met by the use of recent transfusions, or growth factor support (granulocyte colony-stimulating factor [G-CSF], erythropoietin, etc.) within  weeks prior to treatment initiation
DONOR: Must consent to granulocyte-colony stimulating factor (G-CSF) (filgrastim) administration and leukapheresis for both PBSC allograft and subsequent donor lymphocyte infusion (DLI)
It must have been at least  days since the completion of therapy with granulocyte colony stimulating factor (GCSF) or other growth factors at the time of enrollment; it must have been at least  days since the completion of therapy with pegfilgrastim (Neulasta)
Patients must have a healthy blood-related donor (parent, child, sibling) willing to undergo apheresis after granulocyte colony-stimulating factor (G-CSF) administration
Hematopoietic growth factor receptor agonists (eg, erythropoietin (Epo), granulocyte colony stimulating factor, romiplostim, eltrombopag within  days of enrollment.
Patients should have finished their prior systemic therapy or radiation therapy, at least  weeks before cyclophosphamide or granulocyte colony-stimulating factor (G-CSF)/plerixafor mobilization, and should have finished dexamethasone at least  days prior to Plerixafor priming; administration of bisphosphonates needs to be completed at least  weeks before cyclophosphamide priming; bisphosphonates can be resumed or started after day 
Inclusion:\n\n          . Male or female infants, children and adolescents aged  month to < years.\n\n          . Patients with solid tumors without bone marrow involvement, who are scheduled to\n             receive myelosuppressive CTX.\n\n          . Body weight ? kg.\n\n          . Patients must have an initial diagnosis and histologic proof of their malignancy. All\n             enrolled subjects should have signed consent for a CTX regimen that is known to be\n             myelotoxic, with counts expected to drop below the absolute neutrophil count (ANC) of\n             .  /L for at least  days. These regimens would include at least one of the\n             following:\n\n               -  Etoposide\n\n               -  doxorubicin\n\n               -  ifosfamide\n\n               -  cyclophosphamide\n\n          . ANC and platelet count: Patients must have an ANC >  /L and a platelet count >\n              /L to be eligible for therapy at the start of CTX.\n\n          . Normal cardiac, renal, and hepatic function.\n\n          . All subjects must have a life expectancy of  weeks or more.\n\n          . Performance Status: Lansky performance score > (age  to < years).\n\n               -  More criteria may apply, please contact the investigator for more information.\n\n        Exclusion:\n\n          . Bone marrow involvement.\n\n          . Active myelogenous leukemia or history of myelogenous leukemia.\n\n          . Previous treatment with colony-stimulating factors (granulocyte colony-stimulating\n             factor [G-CSF], granulocyte-macrophage colony-stimulating factor, interleukin \n             [IL-]) less than  weeks prior to study entry.\n\n          . History of congenital neutropenia or cyclic neutropenia.\n\n          . Pregnant or nursing female patients.\n\n          . Fertile patients who do not agree to use highly reliable contraceptive measures Prior\n             bone marrow or stem cell transplant, or prior radiation to ?% of bone marrow within\n             the  weeks prior to the first tbo-filgrastim dose.\n\n          . Ongoing active infection or history of infectious disease within  weeks prior to the\n             screening visit.\n\n          . Treatment with lithium at screening or planned during the study\n\n               -  More criteria may apply, please contact the investigator for more information.
Receiving prophylactic use of hematopoietic colony stimulating factors
Requirement for routine use of hematopoietic growth factors (including granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, or interleukin-) or platelet transfusions to maintain absolute neutrophil counts or platelets counts above the required thresholds for study entry
Adequate organ function, defined as (Note: CBC test should be obtained without transfusion or receipt of colony stimulating factors within  weeks before obtaining sample):
Receiving erythropoietin stimulating agents prior to admission
Receiving erythropoietin stimulating agent
At the time of the wire stimulating procedure, patients will be excluded if the surgeon is unable to place the temporary stimulating lead
Current systemic treatment for AML, with the exception of granulocyte colony-stimulating factor (G-CSF) must have been discontinued at least  days prior to entry into the study; in addition:\r\n* At least  weeks before day  for interleukin (IL)- (oprelvekin)\r\n* At least  weeks before day  for antithymocyte/antilymphocyte globulin
DONOR: Willing to receive Triplex vaccination, a minimum of  days prior to the start of granulocyte stimulating factor (GSF) mobilization
Hemoglobin > . g/dL without transfusion or growth factor support for at least  days prior to screening (with the exception of pegylated granulocyte-colony stimulating factor [G-CSF] and darbopoietin, which require at least  days of abstinence prior to screening)
Treatment with marrow stimulating agents (e.g. granulocyte colony stimulating factor [GCSF]) within  weeks of baseline scan
The patient is receiving colony stimulating factors (CSFs) that cannot be held during the monitoring period for dose-limiting toxicities (DLT).
